Evogene Ltd Ordinary Shares (EVGN)

FairStock Score: 16/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I see a computational biology company with 38 employees, three segments, and a market value of just $9.6 million. In its fiscal Q2 2026, revenue was $347,000 and net loss was $1.8 million, a negative 509.51% margin. Trailing free cash flow is negative $11.0 million, which against the $9.6 million market cap is a -114.0% FCF yield calculated by FairStock. That is not owner earnings; it is capital consumption. Revenue growth is -35.02%, while profit growth is 60.38%, but from deeply negative levels. FairStock calculations show ROE of -182.75%, ROCE of -37.80%, debt/equity of 0.36, Piotroski F-Score of 3/9, and Altman Z-Score of -29.38. Based on the $0.39 close on 2026-10-13, FairStock shows a P/E of -0.22 and no P/B. A moat is unproven: AI-driven small molecules and seed traits may carry intellectual property, but at this revenue scale and cash burn, competitive advantage is speculative. Growth is a hope, not a record. The 52-week range of $0.35 to $1.35 shows how far sentiment has fallen. A low price with negative owner earnings can be a value trap. Graham would demand a margin of safety in assets or earnings; here FairStock's 16/100 score and the lack of a three-year Lynch category suggest neither is established. I would wait for cash flow and commercial validation.

In plain English: Evogene is a small computational biology company with 38 employees, working on agriculture, human health, and industrial applications. It is losing money, with very little revenue and large cash losses; in its latest quarter labeled fiscal Q2 2026, revenue was $347,000 and net loss was $1.8 million. At $0.39 per share on 2026-10-13, the price may look low, but the business fundamentals look very weak and it is not clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer